Abivax

ISIN US00370M1036

 | 

WKN A3EWCP

Market cap (in EUR)
6,845 m
Country
France
Sector
Healthcare
 

Overview

Description

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals France

Financials

Key metrics

Market capitalisation, EUR 6,845 m
EPS, EUR -4.53
P/B ratio 16.3
P/E ratio -
Dividend yield -

Income statement (2025)

Revenue, EUR -
Net income, EUR -336 m
Profit margin -
Advertisement
JPMorgan
JPM Equity Premium Income Active ETFs
Upgrade your income.
Explore
Capital at risk

What ETF is Abivax in?

There are 3 ETFs which contain Abivax. All of these ETFs are listed in the table below. The ETF with the largest weighting of Abivax is the Harbor Health Care UCITS ETF Accumulating.
ETF Weight Investment focus Fund size (in m EUR)
Harbor Health Care UCITS ETF Accumulating 4.88%
Equity
World
Health Care
Innovation
12
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.58%
Equity
United States
Health Care
Biotech
49
iShares Nasdaq US Biotechnology UCITS ETF 0.58%
Equity
United States
Health Care
Biotech
809
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.